The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs (2024)
- Authors:
- USP affiliated authors: FERREIRA, LEONARDO LUIZ GOMES - IFSC ; MASCARENHAS, YVONNE PRIMERANO - IFSC ; ANDRICOPULO, ADRIANO DEFINI - IFSC
- Unidade: IFSC
- DOI: 10.1080/17568919.2024.2379231
- Subjects: FÁRMACOS; PLANEJAMENTO DE FÁRMACOS; DOENÇAS PARASITÁRIAS; DOENÇA DE CHAGAS; TRYPANOSOMA CRUZI
- Keywords: Antiparasitic compounds; Betamethasone; Computational chemistry and molecular modelling; Drug repositioning; Helminthiasis; Medicinal chemistry; Praziquantel; Schistosomiasis; Schistosomicidal; Virtual screening
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Future Medicinal Chemistry
- ISSN: 1756-8919
- Volume/Número/Paginação/Ano: v. 16, n. 17, p. 1791-1799, 2024
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
DOBRACHINSKI, Leandro et al. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, v. 16, n. 17, p. 1791-1799, 2024Tradução . . Disponível em: https://doi.org/10.1080/17568919.2024.2379231. Acesso em: 24 fev. 2026. -
APA
Dobrachinski, L., Ferreira, L. L. G., Cirino, M. E. de, Siqueira, A. I. A. de, Mafud, A. C., Mascarenhas, Y. P., et al. (2024). The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. Future Medicinal Chemistry, 16( 17), 1791-1799. doi:10.1080/17568919.2024.2379231 -
NLM
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1080/17568919.2024.2379231 -
Vancouver
Dobrachinski L, Ferreira LLG, Cirino ME de, Siqueira AIA de, Mafud AC, Mascarenhas YP, Andricopulo AD, Moraes J de. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs [Internet]. Future Medicinal Chemistry. 2024 ; 16( 17): 1791-1799.[citado 2026 fev. 24 ] Available from: https://doi.org/10.1080/17568919.2024.2379231 - Novel brominated vinylic fatty acids effectively inhibit the leishmania topoisomerase IB enzyme mediated by halogen bond formation
- 3D QSAR studies for a series of Trypanosoma cruzi dehydrogenase inhibitors
- COVID-19: small-molecule clinical trials landscape [Editorial]
- Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies
- Cancer estimates in Brazil reveal progress for the most lethal malignancies [Editorial]
- In vitro leishmanicidal activity of novel N-arylspermidine derivatives
- Chemoinformatics approaches to structure- and ligand-based drug design
- Empowering neglected tropical disease drug discovery with translational medicinal chemistry. [Editorial]
- World chagas disease day and the new road map for neglected tropical diseases. [Editorial]
- Evaluation of pyrazolines as anti-alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies
Informações sobre o DOI: 10.1080/17568919.2024.2379231 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
PROD036326_3218883.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
